Difference between revisions of "Rhabdomyosarcoma, pediatric - historical"
m (→References) |
m |
||
Line 4: | Line 4: | ||
</div> | </div> | ||
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Rhabdomyosarcoma, pediatric|pediatric rhabdomyosarcoma page]] for current regimens. | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Rhabdomyosarcoma, pediatric|pediatric rhabdomyosarcoma page]] for current regimens. | ||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 11: | Line 10: | ||
|} | |} | ||
{{TOC limit|limit=4}} | {{TOC limit|limit=4}} | ||
− | |||
=Unstratified, all lines of therapy= | =Unstratified, all lines of therapy= | ||
==Dactinomycin monotherapy {{#subobject:a9367b|Regimen=1}}== | ==Dactinomycin monotherapy {{#subobject:a9367b|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:43c238|Variant=1}}=== | ===Regimen {{#subobject:43c238|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
Line 24: | Line 22: | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Dactinomycin (Cosmegen)]] | *[[Dactinomycin (Cosmegen)]] | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
# Pinkel D. Actinomycin D in childhood cancer; a preliminary report. Pediatrics. 1959 Feb;23(2):342-7. [https://doi.org/10.1542/peds.23.2.342 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13633349 PubMed] | # Pinkel D. Actinomycin D in childhood cancer; a preliminary report. Pediatrics. 1959 Feb;23(2):342-7. [https://doi.org/10.1542/peds.23.2.342 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13633349 PubMed] | ||
− | |||
=High Risk, all lines of therapy= | =High Risk, all lines of therapy= | ||
==COG D9802 VCPT Alternating with VAC Arm== | ==COG D9802 VCPT Alternating with VAC Arm== | ||
− | === | + | <div class="toccolours" style="background-color:#c8a2c8"> |
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Years of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/JCO.2006.07.1720 Pappo et al. 2007 (COG D9802)] | ||
+ | |9/1999-11/2000 | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Protocol, Irinotecan Window=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 0 (VCPT)==== | ====Chemotherapy, Week 0 (VCPT)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 48: | Line 59: | ||
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | **[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | ||
====Chemotherapy, Week 2 Off Chemo==== | ====Chemotherapy, Week 2 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 3 (VCPT)==== | ====Chemotherapy, Week 3 (VCPT)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 64: | Line 74: | ||
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | **[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | ||
====Chemotherapy, Week 5 Evaluation==== | ====Chemotherapy, Week 5 Evaluation==== | ||
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Induction=== | |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy, Week 6 (VAC)==== | ====Chemotherapy, Week 6 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 145: | Line 147: | ||
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | **Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | ||
====Chemotherapy, Week 14 Evaluation==== | ====Chemotherapy, Week 14 Evaluation==== | ||
− | |||
====Chemotherapy, Week 15 (Vincristine)==== | ====Chemotherapy, Week 15 (Vincristine)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 190: | Line 191: | ||
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | **Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | ||
====Chemotherapy, Week 20 through 22 Off Chemo==== | ====Chemotherapy, Week 20 through 22 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 23 (VAC)==== | ====Chemotherapy, Week 23 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 219: | Line 219: | ||
**Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1 | **Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1 | ||
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | **Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | ||
− | === | + | </div></div><br> |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Continuation=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 26 (VCPT)==== | ====Chemotherapy, Week 26 (VCPT)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 235: | Line 238: | ||
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | **[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | ||
====Chemotherapy, Week 28 Off Chemo==== | ====Chemotherapy, Week 28 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 29 (VAC)==== | ====Chemotherapy, Week 29 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 254: | Line 256: | ||
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | **Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | ||
====Chemotherapy, Week 30 through 31 Off Chemo==== | ====Chemotherapy, Week 30 through 31 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 32 (VCPT)==== | ====Chemotherapy, Week 32 (VCPT)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 292: | Line 293: | ||
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | **Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | ||
====Chemotherapy, Week 36 through 37 Off Chemo==== | ====Chemotherapy, Week 36 through 37 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 38 (VCPT)==== | ====Chemotherapy, Week 38 (VCPT)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 308: | Line 308: | ||
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | **[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | ||
====Chemotherapy, Week 40 Off Chemo==== | ====Chemotherapy, Week 40 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 41 (VAC)==== | ====Chemotherapy, Week 41 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 327: | Line 326: | ||
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | **Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | ||
====Chemotherapy, Week 42 through 43 Off Chemo==== | ====Chemotherapy, Week 42 through 43 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 44 Evaluation==== | ====Chemotherapy, Week 44 Evaluation==== | ||
− | + | </div></div></div> | |
===References=== | ===References=== | ||
− | # '''COG D9802:''' Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. | + | # '''COG D9802:''' Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):362-9. [https://doi.org/10.1200/JCO.2006.07.1720 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00003955 |
− | |||
==COG D9802 VAC Alone Arm== | ==COG D9802 VAC Alone Arm== | ||
− | === | + | <div class="toccolours" style="background-color:#c8a2c8"> |
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Years of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/JCO.2006.07.1720 Pappo et al. 2007 (COG D9802)] | ||
+ | |9/1999-11/2000 | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Protocol, Irinotecan Window=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 0 (VCPT)==== | ====Chemotherapy, Week 0 (VCPT)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 350: | Line 360: | ||
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | **[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | ||
====Chemotherapy, Week 2 Off Chemo==== | ====Chemotherapy, Week 2 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 3 (VCPT)==== | ====Chemotherapy, Week 3 (VCPT)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 366: | Line 375: | ||
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | **[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]] | ||
====Chemotherapy, Week 5 Evaluation==== | ====Chemotherapy, Week 5 Evaluation==== | ||
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | === | + | ===Induction=== |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 6 (VAC)==== | ====Chemotherapy, Week 6 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 438: | Line 448: | ||
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | **Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | ||
====Chemotherapy, Week 14 Evaluation==== | ====Chemotherapy, Week 14 Evaluation==== | ||
− | |||
====Chemotherapy, Week 15 (Vincristine)==== | ====Chemotherapy, Week 15 (Vincristine)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 483: | Line 492: | ||
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | **Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | ||
====Chemotherapy, Week 20 through 22 Off Chemo==== | ====Chemotherapy, Week 20 through 22 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 23 (VAC)==== | ====Chemotherapy, Week 23 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 511: | Line 519: | ||
**Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1 | **Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1 | ||
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | **Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | ||
− | === | + | </div></div><br> |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Continuation=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 26 (VAC)==== | ====Chemotherapy, Week 26 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 535: | Line 546: | ||
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | **Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1 | ||
====Chemotherapy, Week 28 Off Chemo==== | ====Chemotherapy, Week 28 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 29 (VAC)==== | ====Chemotherapy, Week 29 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 554: | Line 564: | ||
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | **Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | ||
====Chemotherapy, Week 30 through 31 Off Chemo==== | ====Chemotherapy, Week 30 through 31 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 32 (VAC)==== | ====Chemotherapy, Week 32 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 600: | Line 609: | ||
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | **Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | ||
====Chemotherapy, Week 36 through 37 Off Chemo==== | ====Chemotherapy, Week 36 through 37 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 38 (VAC)==== | ====Chemotherapy, Week 38 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 619: | Line 627: | ||
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | **Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | ||
====Chemotherapy, Week 39 through 40 Off Chemo==== | ====Chemotherapy, Week 39 through 40 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 41 (VAC)==== | ====Chemotherapy, Week 41 (VAC)==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 638: | Line 645: | ||
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | **Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1 | ||
====Chemotherapy, Week 42 through 43 Off Chemo==== | ====Chemotherapy, Week 42 through 43 Off Chemo==== | ||
− | |||
====Chemotherapy, Week 44 Evaluation==== | ====Chemotherapy, Week 44 Evaluation==== | ||
+ | </div></div></div> | ||
===References=== | ===References=== | ||
− | # '''COG D9802:''' Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. | + | # '''COG D9802:''' Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):362-9. [https://doi.org/10.1200/JCO.2006.07.1720 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00003955 |
− | |||
=Low Risk, all lines of therapy= | =Low Risk, all lines of therapy= | ||
==COG D9602 Subgroup A Clinical Group 1== | ==COG D9602 Subgroup A Clinical Group 1== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
Line 655: | Line 663: | ||
|- | |- | ||
|} | |} | ||
− | == | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | |||
====Chemotherapy, Week 0==== | ====Chemotherapy, Week 0==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 718: | Line 725: | ||
====Chemotherapy, Week 10 and 11 Off Chemo==== | ====Chemotherapy, Week 10 and 11 Off Chemo==== | ||
====Chemotherapy, Week 12 Evaluation==== | ====Chemotherapy, Week 12 Evaluation==== | ||
+ | '''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | #'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | ||
− | |||
==COG D9602 Subgroup A Clinical Group 2== | ==COG D9602 Subgroup A Clinical Group 2== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen=== | ===Regimen=== | ||
− | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" | |
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Years of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)] | ||
+ | |9/1/1997-9/17/2004 | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 0==== | ====Chemotherapy, Week 0==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 783: | Line 802: | ||
====Chemotherapy, Week 10 and 11 Off Chemo==== | ====Chemotherapy, Week 10 and 11 Off Chemo==== | ||
====Chemotherapy, Week 12 Evaluation==== | ====Chemotherapy, Week 12 Evaluation==== | ||
+ | '''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | #'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | ||
− | |||
==COG D9602 Subgroup A Clinical Group 3== | ==COG D9602 Subgroup A Clinical Group 3== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen=== | ===Regimen=== | ||
− | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" | |
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Years of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)] | ||
+ | |9/1/1997-9/17/2004 | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 0==== | ====Chemotherapy, Week 0==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 848: | Line 879: | ||
====Chemotherapy, Week 10 and 11 Off Chemo==== | ====Chemotherapy, Week 10 and 11 Off Chemo==== | ||
====Chemotherapy, Week 12 Evaluation==== | ====Chemotherapy, Week 12 Evaluation==== | ||
+ | '''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | #'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | ||
− | |||
==COG D9602 Subgroup B Clinical Group 1== | ==COG D9602 Subgroup B Clinical Group 1== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen=== | ===Regimen=== | ||
− | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" | |
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Years of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)] | ||
+ | |9/1/1997-9/17/2004 | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 0==== | ====Chemotherapy, Week 0==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 955: | Line 998: | ||
====Chemotherapy, Week 10 and 11 Off Chemo==== | ====Chemotherapy, Week 10 and 11 Off Chemo==== | ||
====Chemotherapy, Week 12 Evaluation==== | ====Chemotherapy, Week 12 Evaluation==== | ||
+ | '''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | #'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | ||
− | |||
==COG D9602 Subgroup B Clinical Group 2== | ==COG D9602 Subgroup B Clinical Group 2== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen=== | ===Regimen=== | ||
− | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" | |
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Years of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)] | ||
+ | |9/1/1997-9/17/2004 | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 0==== | ====Chemotherapy, Week 0==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 1,009: | Line 1,064: | ||
====Radiotherapy, Week 3==== | ====Radiotherapy, Week 3==== | ||
*[[External beam radiotherapy]] 36 Gy given once daily in 20 divided fractions | *[[External beam radiotherapy]] 36 Gy given once daily in 20 divided fractions | ||
− | |||
====Chemotherapy, Week 4==== | ====Chemotherapy, Week 4==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 1,061: | Line 1,115: | ||
====Chemotherapy, Week 10 and 11 Off Chemo==== | ====Chemotherapy, Week 10 and 11 Off Chemo==== | ||
====Chemotherapy, Week 12 Evaluation==== | ====Chemotherapy, Week 12 Evaluation==== | ||
+ | '''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | #'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | ||
− | |||
==COG D9602 Subgroup B Clinical Group 3== | ==COG D9602 Subgroup B Clinical Group 3== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen=== | ===Regimen=== | ||
− | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" | |
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Years of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)] | ||
+ | |9/1/1997-9/17/2004 | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy, Week 0==== | ====Chemotherapy, Week 0==== | ||
*[[Vincristine (Oncovin)]] by the following age-based criteria: | *[[Vincristine (Oncovin)]] by the following age-based criteria: | ||
Line 1,167: | Line 1,232: | ||
====Chemotherapy, Week 10 and 11 Off Chemo==== | ====Chemotherapy, Week 10 and 11 Off Chemo==== | ||
====Chemotherapy, Week 12 Evaluation==== | ====Chemotherapy, Week 12 Evaluation==== | ||
− | + | '''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | #'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995 | ||
− | |||
[[Category:Bone sarcomas]] | [[Category:Bone sarcomas]] | ||
[[Category:Historical regimens]] | [[Category:Historical regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Pediatric solid tumors]] | [[Category:Pediatric solid tumors]] |
Revision as of 02:18, 3 March 2023
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the pediatric rhabdomyosarcoma page for current regimens.
1 regimens on this page
1 variants on this page
|
Unstratified, all lines of therapy
Dactinomycin monotherapy
References
- Pinkel D. Actinomycin D in childhood cancer; a preliminary report. Pediatrics. 1959 Feb;23(2):342-7. link to original article PubMed
High Risk, all lines of therapy
COG D9802 VCPT Alternating with VAC Arm
Study | Years of enrollment | Evidence |
---|---|---|
Pappo et al. 2007 (COG D9802) | 9/1999-11/2000 | Phase 2 |
Protocol, Irinotecan Window
Chemotherapy, Week 0 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 1 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 2 Off Chemo
Chemotherapy, Week 3 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 4 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 5 Evaluation
Induction
Chemotherapy, Week 6 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 6
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 7 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 8 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 9 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 10 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 11 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 12 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 12
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 13 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 14 Evaluation
Chemotherapy, Week 15 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 16 (VC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 16
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 17 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 18 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 19 (VC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 19
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 20 through 22 Off Chemo
Chemotherapy, Week 23 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 23
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 24 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 25 (Eval/Vincristine)
- Evaluation Week
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Continuation
Chemotherapy, Week 26 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 27 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 28 Off Chemo
Chemotherapy, Week 29 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 29
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 30 through 31 Off Chemo
Chemotherapy, Week 32 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 33 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 34 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 35 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 35
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 36 through 37 Off Chemo
Chemotherapy, Week 38 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 39 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 40 Off Chemo
Chemotherapy, Week 41 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 41
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 42 through 43 Off Chemo
Chemotherapy, Week 44 Evaluation
References
- COG D9802: Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):362-9. link to original article PubMed NCT00003955
COG D9802 VAC Alone Arm
Study | Years of enrollment | Evidence |
---|---|---|
Pappo et al. 2007 (COG D9802) | 9/1999-11/2000 | Phase 2 |
Protocol, Irinotecan Window
Chemotherapy, Week 0 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 1 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 2 Off Chemo
Chemotherapy, Week 3 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 4 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 5 Evaluation
Induction
Chemotherapy, Week 6 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 6
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 7 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 8 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 9 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 10 (VCPT)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5
- Irinotecan (Camptosar) to be given after Vincristine (Oncovin)
Chemotherapy, Week 11 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 12 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 12
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 13 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 14 Evaluation
Chemotherapy, Week 15 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 16 (VC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 16
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 17 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 18 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 19 (VC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 19
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 20 through 22 Off Chemo
Chemotherapy, Week 23 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 23
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 24 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 25 (Evaluation/Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Continuation
Chemotherapy, Week 26 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 26
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 27 (VCR)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 28 Off Chemo
Chemotherapy, Week 29 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 29
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 30 through 31 Off Chemo
Chemotherapy, Week 32 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 32
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 33 (VCR)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 34 (Vincristine)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 35 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 35
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 36 through 37 Off Chemo
Chemotherapy, Week 38 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 38
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 39 through 40 Off Chemo
Chemotherapy, Week 41 (VAC)
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 41
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
Chemotherapy, Week 42 through 43 Off Chemo
Chemotherapy, Week 44 Evaluation
References
- COG D9802: Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):362-9. link to original article PubMed NCT00003955
Low Risk, all lines of therapy
COG D9602 Subgroup A Clinical Group 1
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Raney et al. 2011 (IRSG D9602) | 9/1/1997-9/17/2004 | Phase 2 |
Chemotherapy, Week 0
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
Chemotherapy, Week 1
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 2
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 3
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- No External beam radiotherapy
Chemotherapy, Week 4
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 5
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 6
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
Chemotherapy, Week 7
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 8
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 9
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
Chemotherapy, Week 10 and 11 Off Chemo
Chemotherapy, Week 12 Evaluation
12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36
References
- IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995
COG D9602 Subgroup A Clinical Group 2
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Raney et al. 2011 (IRSG D9602) | 9/1/1997-9/17/2004 | Phase 2 |
Chemotherapy, Week 0
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
Chemotherapy, Week 1
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 2
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 3
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
Radiotherapy, Week 3
- External beam radiotherapy 36 Gy given once daily in 20 divided fractions
Chemotherapy, Week 4
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 5
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 6
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 7
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 8
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 9
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
Chemotherapy, Week 10 and 11 Off Chemo
Chemotherapy, Week 12 Evaluation
12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36
References
- IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995
COG D9602 Subgroup A Clinical Group 3
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Raney et al. 2011 (IRSG D9602) | 9/1/1997-9/17/2004 | Phase 2 |
Chemotherapy, Week 0
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
Chemotherapy, Week 1
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 2
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 3
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
Radiotherapy, Week 3
- External beam radiotherapy 45 Gy given once daily in 25 divided fractions
Chemotherapy, Week 4
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 5
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 6
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 7
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 8
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 9
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
Chemotherapy, Week 10 and 11 Off Chemo
Chemotherapy, Week 12 Evaluation
12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36
References
- IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995
COG D9602 Subgroup B Clinical Group 1
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Raney et al. 2011 (IRSG D9602) | 9/1/1997-9/17/2004 | Phase 2 |
Chemotherapy, Week 0
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 0
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL
Chemotherapy, Week 1
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 2
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 3
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 3
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL
- No External beam radiotherapy
Chemotherapy, Week 4
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 5
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 6
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 6
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL
Chemotherapy, Week 7
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 8
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 9
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 9
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after AC completion and continued once daily for 10 days or until ANC > 2000/μL
Chemotherapy, Week 10 and 11 Off Chemo
Chemotherapy, Week 12 Evaluation
12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36
References
- IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995
COG D9602 Subgroup B Clinical Group 2
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Raney et al. 2011 (IRSG D9602) | 9/1/1997-9/17/2004 | Phase 2 |
Chemotherapy, Week 0
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 0
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL
Chemotherapy, Week 1
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 2
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 3
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 3
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL
Radiotherapy, Week 3
- External beam radiotherapy 36 Gy given once daily in 20 divided fractions
Chemotherapy, Week 4
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 5
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 6
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 6
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL
Chemotherapy, Week 7
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 8
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 9
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 9
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after AC completion and continued once daily for 10 days or until ANC > 2000/μL
Chemotherapy, Week 10 and 11 Off Chemo
Chemotherapy, Week 12 Evaluation
12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36
References
- IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995
COG D9602 Subgroup B Clinical Group 3
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Raney et al. 2011 (IRSG D9602) | 9/1/1997-9/17/2004 | Phase 2 |
Chemotherapy, Week 0
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 0
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL
Chemotherapy, Week 1
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 2
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 3
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 3
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL
Radiotherapy, Week 3
- External beam radiotherapy 45 Gy given once daily in 25 divided fractions
Chemotherapy, Week 4
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 5
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 6
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 6
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL
Chemotherapy, Week 7
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 8
- Vincristine (Oncovin) by the following age-based criteria:
- Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
- Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Chemotherapy, Week 9
- Dactinomycin (Cosmegen) by the following age-based criteria:
- Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
- Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
- Cyclophosphamide (Cytoxan) by the following age-based criteria:
- Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
- Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
- Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1
Supportive Medications, Week 9
- Mesna (Mesnex) by the following age-based criteria:
- Age ≥ 3 years: 440 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age ≥ 1 year: 14.6 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Age < 1 year: 7.2 mg/m2 IV infusion at hour 0, 4, and 8 from the start of each Cyclophosphamide (Cytoxan) infusion on day 1
- Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after AC completion and continued once daily for 10 days or until ANC > 2000/μL
Chemotherapy, Week 10 and 11 Off Chemo
Chemotherapy, Week 12 Evaluation
12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36
References
- IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995